GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.